ARTICLE | Clinical News
ATB-346: Phase II data
August 15, 2016 7:00 AM UTC
An open-label, Canadian Phase II trial in 12 patients with OA of the knee showed that once-daily 250 mg oral ATB-346 reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain...